Recursion Pharmaceuticals (RXRX) Intangibles (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Intangibles came in at $294.1 million in Q1 2026, down 12.42% YoY from $335.8 million in Q1 2025, and down 5.11% on a QoQ basis from $309.9 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) Intangibles (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of Intangibles data on file, last reported at $294.1 million in Q1 2026.
- Quarterly Intangibles fell 12.42% year-over-year to $294.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $294.1 million (down 12.42% YoY) and the FY2025 annual result came in at $309.9 million, down 7.73% from the prior year.
- Intangibles eased to $294.1 million in Q1 2026, from $309.9 million in the prior quarter.
- In the past five years, Intangibles ranged from a high of $341.3 million in Q2 2025 to a low of $1.2 million in Q2 2022.
- A 5-year average of $127.6 million and a median of $38.2 million in 2024 frame the typical range for Intangibles.
- Annual changes were most pronounced in 2023 — Intangibles soared 3367.72% — and 2024, when it declined 13.6%.
- Tracing RXRX's Intangibles over 5 years: stood at $1.3 million in 2022, then soared by 2690.43% to $36.4 million in 2023, then surged by 821.59% to $335.9 million in 2024, then decreased by 7.73% to $309.9 million in 2025, then slipped by 5.11% to $294.1 million in 2026.
- The last three Intangibles figures came in at $294.1 million (Q1 2026), $309.9 million (Q4 2025), and $322.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | 282.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 282.89 Mn |
| Mar 31, 2026 | 294.07 Mn |
| Dec 31, 2025 | 309.90 Mn |
| Sep 30, 2025 | 322.34 Mn |
| Jun 30, 2025 | 341.32 Mn |
| Mar 31, 2025 | 335.79 Mn |
| Dec 31, 2024 | 335.86 Mn |
| Sep 30, 2024 | 34.09 Mn |
| Jun 30, 2024 | 38.21 Mn |
| Mar 31, 2024 | 33.08 Mn |
| Dec 31, 2023 | 36.44 Mn |
| Sep 30, 2023 | 39.46 Mn |
| Jun 30, 2023 | 42.76 Mn |
| Mar 31, 2023 | 1.32 Mn |
| Dec 31, 2022 | 1.31 Mn |
| Sep 30, 2022 | 1.46 Mn |
| Jun 30, 2022 | 1.23 Mn |
| Mar 31, 2022 | 1.31 Mn |
| Dec 31, 2021 | 1.39 Mn |
| Dec 31, 2020 | 1.69 Mn |